-
公开(公告)号:US09999593B2
公开(公告)日:2018-06-19
申请号:US12995351
申请日:2009-05-28
申请人: Timo Reunamaki , Pertti Pellinen , Olli Oksala , Kari Lehmussaari
发明人: Timo Reunamaki , Pertti Pellinen , Olli Oksala , Kari Lehmussaari
CPC分类号: A61K9/0048 , A61K9/08 , A61K31/5575 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/26 , Y02A50/465
摘要: The present invention relates to an ophthalmic aqueous composition containing PGF2α analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogs in an aqueous composition.
-
2.
公开(公告)号:US20110152264A1
公开(公告)日:2011-06-23
申请号:US12995351
申请日:2009-05-28
申请人: Timo Reunamaki , Pertti Pellinen , Olli Oksala , Kari Lehmussaari
发明人: Timo Reunamaki , Pertti Pellinen , Olli Oksala , Kari Lehmussaari
IPC分类号: A61K31/5377 , A61K31/215 , A61P27/02
CPC分类号: A61K9/0048 , A61K9/08 , A61K31/5575 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/26 , Y02A50/465
摘要: The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogues in an aqueous composition.
摘要翻译: 本发明涉及一种含有用于治疗高眼压症和青光眼的PGF2α类似物的眼用含水组合物,通过将所述组合物施用于需要这种治疗的受试者,治疗高眼压症和青光眼的方法,以及提高水溶性的方法和 PGF2α类似物在水性组合物中的稳定性。
-
公开(公告)号:US5767143A
公开(公告)日:1998-06-16
申请号:US542714
申请日:1995-10-13
申请人: Kari Lehmussaari , Olli Oksala , Timo Reunamaki
发明人: Kari Lehmussaari , Olli Oksala , Timo Reunamaki
CPC分类号: A61K9/0048 , Y10S514/912
摘要: The present invention relates to an eye drop formulation, which, in combination, comprises a single polymer, pilocarpine, a beta-blocking agent and an ophthalmologically acceptable carrier wherein the pH of the formulation is from 3.5 to 5.8 and the viscosity is from 10 to 25000 mPas.
摘要翻译: 本发明涉及一种眼药水制剂,其组合包含单一聚合物,毛果芸香碱,β-阻断剂和眼科学上可接受的载体,其中制剂的pH为3.5至5.8,粘度为10至 25000 mPas。
-
公开(公告)号:US5710182A
公开(公告)日:1998-01-20
申请号:US535037
申请日:1996-04-02
CPC分类号: A61K9/0048 , Y10S514/912
摘要: The present invention is directed to an ophthalmic composition in the form of a topical aqueous solution consisting essentially of an ophthalmologically active agent, an ion sensitive, hydrophilic polymer in an amount a of 0.004 to 1.5% by weight, at least one salt selected from the group of inor ganic salts and buffers in a total amount of from 0.01 to 2.0% by weight, a wetting agent in an amount of 0 to 3.0% by weight, a preservative in an amount of 0 to 0.02% by weight, water, and optionally a pH regulating agent in an amount sufficient to give a pH of 4.0 to 8.0 to the composition, the ratio between salt and polymer components being such that the solution exhibits a viscosity of less than 1000 mPas. The composition contains a sufficient amount of polymer to provide for a controlled absorption of the drug into the eye, its viscosity having been reduced to provide for better handling characteristics.
摘要翻译: PCT No.PCT / FI95 / 00166 Sec。 371日期:1996年4月2日 102(e)日期1996年4月2日PCT 1995年3月29日PCT PCT。 第WO95 / 26711号公报 日期1995年10月12日本发明涉及一种局部水溶液形式的眼用组合物,其基本上由眼科活性剂,离子敏感性亲水性聚合物,其量a至少为0.004至1.5% 一种盐,其选自总重量为0.01至2.0重量%的非导入盐和缓冲剂组,润湿剂的量为0至3.0重量%,防腐剂的量为0至0.02%,通过 重量,水和任选的pH调节剂,其量足以使组合物的pH为4.0至8.0,盐和聚合物组分之间的比例使得溶液表现出小于1000mPa·s的粘度。 组合物含有足够量的聚合物以提供药物对眼睛的受控吸收,其粘度已经降低以提供更好的处理特性。
-
公开(公告)号:US5795913A
公开(公告)日:1998-08-18
申请号:US535033
申请日:1996-03-15
申请人: Kari Lehmussaari , Eija Vartiainen , Timo Reunamaki , Olli Oksala , Sakari Alaranta , Esko Pohjala
发明人: Kari Lehmussaari , Eija Vartiainen , Timo Reunamaki , Olli Oksala , Sakari Alaranta , Esko Pohjala
IPC分类号: A61K9/08 , A61K9/00 , A61K31/02 , A61K31/535 , A61K47/32 , A61K47/34 , A61K47/36 , A61P27/02 , A61P27/06 , A61K31/35
CPC分类号: A61K9/0048 , A61K47/32 , Y10S514/912
摘要: The present invention is directed to an ophthalmic composition in the form of a topical aqueous solution consisting essentially of an ophthalmologically active agent containing basic groups, an ion sensitive, hydrophilic polymer containing acidic groups in an amount of 0.004 to 1.5% by weight, at least one salt selected from the group of inorganic salts and buffers in a total amount of from 0.01 to 2.0% by weight, and optionally a wetting agent and a preservative, the ratio between salt and polymer being such that the solution exhibits a viscosity of less than 1000 mpas, and the pH of the solution is 4.0 to 8.0. The composition contains a sufficient amount of polymer to provide for a controlled absorption of the drug into the eye, its viscosity having been reduced to provide for better handling characteristics.
摘要翻译: PCT No.PCT / FI95 / 00167 Sec。 371日期:1996年3月15日 102(e)1996年3月15日PCT 1995年3月29日PCT公布。 公开号WO95 / 26712 PCT 日期1995年10月12日本发明涉及一种局部水溶液形式的眼用组合物,其基本上由含有碱性基团的眼科活性剂,含有0.004至1.5%的酸性基团的离子敏感的亲水性聚合物组成, ,至少一种选自无机盐和缓冲剂的盐,其总量为0.01-2.0重量%,以及任选的润湿剂和防腐剂,盐和聚合物之间的比例使得溶液表现出 粘度小于1000mpas,溶液的pH为4.0〜8.0。 组合物含有足够量的聚合物以提供药物对眼睛的受控吸收,其粘度已经降低以提供更好的处理特性。
-
公开(公告)号:US20120107376A1
公开(公告)日:2012-05-03
申请号:US13381631
申请日:2010-06-23
申请人: Timo Reunamaki , Paula Tervo , Jukka Lokkila , Pertti Pellinen , Paivi Alajuuma , Olli Oksala
发明人: Timo Reunamaki , Paula Tervo , Jukka Lokkila , Pertti Pellinen , Paivi Alajuuma , Olli Oksala
IPC分类号: A61K31/216 , A61P27/06 , A61K9/00
CPC分类号: A61K9/0048 , A61K47/18
摘要: The present invention relates to a method for improving ocular bioavailability of latanoprost by adding an organic amine to an aqueous eye drop composition containing latanoprost. The invention further relates to an aqueous eye drop composition in which a better ocular bioavailability of latanoprost is achieved by adding an organic amine, and to a method for treating occular hypertension and glaucoma by administering said composition to a subject in need of such treatment.
摘要翻译: 本发明涉及通过向含有拉坦前列素的含水滴眼液组合物中加入有机胺来改善拉坦前列素的眼部生物利用度的方法。 本发明还涉及一种水性滴眼剂组合物,其中拉坦前列素的更好的眼部生物利用度通过加入有机胺来实现,以及通过将所述组合物施用于需要这种治疗的受试者来治疗高血压和青光眼的方法。
-
-
-
-
-